IL1B and neoplasm: In an upcoming study, we will evaluate IL-1β blockade in the neoadjuvant setting for women with early TNBC, examining changes to key immune biomarkers of the tumor microenvironment (including TILs, TAMs, NK cells, IL-1β and inflammasome expression) using paired samples pre and post anti-IL-1β therapy.